{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["151(5)"],"submitter":["Liang L"],"pubmed_abstract":["<h4>Purpose</h4>Primary central nervous system lymphoma (PCNSL) has a poor prognosis, mainly because of the significant challenges with the efficacy and tolerability of induction chemotherapy. This retrospective study aimed to evaluate the efficacy and safety of the R2-MTX regimen in PCNSL patients.<h4>Methods</h4>We conducted a retrospective analysis of 39 PCNSL patients treated with the R2-MTX regimen, focusing on treatment outcomes and adverse events (AEs).<h4>Results</h4>The overall response rate (ORR) was 72.2%, with a complete response (CR) rate of 69.4% and a partial response (PR) rate of 2.8%. With a median follow-up of 37.2 months (interquartile range [IQR] 24.2-47.5), the estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 54.9% (95% CI, 37.2-69."],"journal":["Journal of cancer research and clinical oncology"],"pagination":["173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12098186"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis."],"pmcid":["PMC12098186"],"pubmed_authors":["Feng Y","Liang L","Xie L","Jiang M","Meng X","Li N"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis.","description":"<h4>Purpose</h4>Primary central nervous system lymphoma (PCNSL) has a poor prognosis, mainly because of the significant challenges with the efficacy and tolerability of induction chemotherapy. This retrospective study aimed to evaluate the efficacy and safety of the R2-MTX regimen in PCNSL patients.<h4>Methods</h4>We conducted a retrospective analysis of 39 PCNSL patients treated with the R2-MTX regimen, focusing on treatment outcomes and adverse events (AEs).<h4>Results</h4>The overall response rate (ORR) was 72.2%, with a complete response (CR) rate of 69.4% and a partial response (PR) rate of 2.8%. With a median follow-up of 37.2 months (interquartile range [IQR] 24.2-47.5), the estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 54.9% (95% CI, 37.2-69.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-05T07:30:23.307Z","creation":"2026-05-14T03:12:17.671Z"},"accession":"S-EPMC12098186","cross_references":{"pubmed":["40402307"],"doi":["10.1007/s00432-025-06205-x"]}}